


DOI at the EPO Accessing cited NPL records



Access to cited NPL

- One of the main priorities for the IP5 industry.
- Today, accessing IP5 file wrapper data is instantaneous and seamless but not cited NPL records.
- This long standing issue has been tackled at the EPO by adding Digital Object Identifiers (DOIs) to the NPL records cited and contained in EPO databases.
- A DOI is a permanent URL to a digital source:
 http://dx.doi.org/10.1097/CJI.0b013e3182594387


How to assign DOIs to NPL?

- Use the service offered by an official Digital Object Identifier (DOI) Registration
 Agency of the International DOI Foundation.
- The EPO uses the services of Crossref an Agency launched in 1998 to support the DOI system.
- Currently used by over 5000 assigners: publishers, science data centres, movie studios, etc.
- Approximately 175 million DOI names assigned to date
- Over 5 billion DOI resolutions per year

How does the EPO proceed?

- Crossref Member since 2005 Membership fee.
- Crossref has a database of bibliographic data from most publisher's articles including the assigned DOI.
- All EPO NPL records (cited or loaded) without DOIs created in the last 6 months are automatically sent to the Crossref database to check if a DOI exists.
- Crossref sends the full matching records to the EPO

DOIs for NPL records: the process



DOI in practice

- 60% of EPO NPL has a DOI
- Improved matching of records between EPO databases
- Improved access for the external users without copyright infringement (ESPACENET and File Inspection)
- Project: identify collections without DOIs and contact the owners to ask them to assign DOIs
- A unique identifier for NPL records with the benefits this brings

Examples from Espacenet

- NPL cited with DOI on <u>EP2950102</u>:
- "Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases"
- DOI: http://dx.doi.org/10.3233/JAD-2011-111202
- NPL cited with DOI on EP3243832:
- "Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy"
- DOI: http://dx.doi.org/10.1097/CJI.0b013e3182594387



Espacenet Patent search

Deutsch English Français Contact Change country -





Quick help

- → What is meant by high quality text as facsimile?

 → What does A1, A2, A3 and B
- stand for after a European publication number? → What happens if I click on "In my
- patents list"?
- → What happens if I click on the "Register" button? → Why are some sidebar options
- deactivated for certain documents?
- → How can I bookmark this page?
- → Why does a list of documents with the heading "Also published as" sometimes appear, and what are these documents?
- → Why do I sometimes find the abstract of a corresponding document?
- → What happens if I click on the red "patent translate" button?
- → What is Global Dossier?

Bibliographic data: EP3243832 (A1) — 2017-11-15



ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER AND PD1 BINDING MOIETY

EP3243832 (A1) - ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER AND PD1 BINDING MOIETY Page bookmark Inventor(s): Applicant(s): F HOFFMANN-LA ROCHE AG [CH] ± Classification: - international: A61K39/395; C07K14/705; C07K16/28; C12N15/62

Priority number(s): EP20160169487 20160513

Also published as: ☐ AR108453 (A1). ☐ AU2017264548 (A1). ☐ CA3023393 (A1). → CO2018012083 (A2). ☐ TW201805306 (A). → more

Abstract of EP3243832 (A1)

Translate this text into [i] patenttranslate powered by EPO and Google Select language

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to PD1 and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

$\ \square$ 4. COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS

*	Inventor: CHEUNG JEANNE [US] KIM JEONG [US]	Applicant: GENENTECH INC [US] HOFFMANN LA ROCHE [CH]	CPC: A61K2039/507 A61K2039/55 A61K38/16 (+6)	IPC: C07K16/28	Publication info: WO2015095423 (A2) 2015-06-25 WO2015095423 (A3) 2015-08-13	Priority date: 2013-12-17
---	---	--	--	-------------------	---	------------------------------

Literature cited in the search report

☐ 5. Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

*	Author: Chen S L-F Lee Fisher T S Jessen B Elliott M Evening W Logronio K Tu G H Tsapankos K Li X Wang H Ying C Xiong M Vanarsdale T Lin J C	Publication data: CANCER IMMUNOLOGY RESEARCH, 20150201 AACR American Association for Cancer Research, US	CPC:	Source information: Vol.3,Nr.2,Page (s):149 - 160	Publication info: XP055293412	
---	---	--	------	--	----------------------------------	--

6. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.

Auti Shin Yosi Kura Wat Ito H Kom Oga Ito H Yosi Haz Tam	ndo Y himura K amasu A anabe Y I do T A	Publication data: ANTICANCER RESEARCH - International Journal of Cancer Research and Treatment, 2015/1011 International Institute of Anticancer Research, GR	CPC:	Source information: Vol.35,Nr.1,Page (s):129 - 136	Publication info: XP002746546	
--	---	---	------	---	----------------------------------	--


7. Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer

*	Author:	Publication data:	CPC:	Source	Publication info:
	Hornig Nora	Journal of Immunotherapy,		information:	XP009163394
	Kermer	20120601 Lippincott Williams & Wilkins, US		Vol:35,Nr:5,Page (s):418 - 429	
	Vanessa Frev Katharina	WIKITS, US		(5).410 - 429	
	Diebolder				
	Philipp				
	Kontermann				
	Roland E				
	Munifor Dafno				



Espacenet Patent search







Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy

Hornig, Nora; Kermer, Vanessa; Frey, Katharina; Diebolder, Philipp; Kontermann, Roland E.; Müller, Dafne

Journal of Immunotherapy: June 2012 - Volume 35 - Issue 5 - p 418-429 doi: 10.1097/CJI.0b013e3182594387 Basic Studies



Abstract

In Brief

Author Information

Article Metrics

Initiation of a tumor-directed immune response and appropriate modulation of its progress are key issues in cancer immunotherapy. Combinatorial strategies addressing both aspects might therefore be especially suitable. Here, we report a targeted approach combining a bispecific antibody with 2 costimulatory antibodyligand fusion proteins. According to the concept, the bispecific antibody (scDbFAP×CD3) retargets T cells in a MHC-independent manner to tumor cells, providing an artificial first signal that allows the costimulatory antibody-ligand fusion proteins (B7.2-Db and scFv-4-1BBL) likewise targeted to the tumor cells to modulate the T-cell response. In our model system, the target cells coexpress the fibroblast activation protein (FAP) and endoglin as antigens. ScDbFAPCD3 and B7.2-Db are targeted to FAP although by different antibody moieties, whereas scFv-4-1BBL is directed against endoglin. ScDbFAPCD3-induced T-cell stimulation could be enhanced by the addition of either B7.2-Db or scFv-4-1BBL and even further by the combination of both as shown in terms of cytokine release (interleukin-2/interferon y), proliferation and activation marker expression (CD25). By combined costimulation, overall T-cell population strongly increased in activation-experienced memory phenotype accompanied by a decrease in naive phenotype. ScFv-4-1BBL-mediated costimulation of naive CD8⁺ T cells promoted the expansion and development of cytotoxic T cells with strong effector potential. Thus, combining a bispecific antibody with antibody-ligand fusion protein-mediated CD28 and 4-1BB costimulation in a targeted approach shows great potential to generate and shape an immune response at the tumor site. Therefore, the adaptation of this approach to other immune modulatory ligands and tumor-relevant targets seems to be promising.



Add to My Favorites Export to Citation Manager

Alert Me When Cited @

Get Content & Permissions

Share this article on:







Article Level Metrics



View full article metrics including social shares, article views and publishing history





EPO orders from external libraries – The other way to access NPL

- Most used libraries:
 - Bayerisches Staatsbibliothek
 - TIB Hannover
 - Subito
 - National Library of Medicine
 - British Library
- 80% of orders delivered to the EPO within 1 working day!

IP5 recommendations

- Affiliate membership with Crossref
- Identify records missing DOIs in internal databases
- Use the query system of Crossref to check if DOIs exist for those records
- Apply the method to the archived NPL and update it on a regular basis
- Contact sources with no DOIs to encourage them to apply DOIs to their publications

Thank You!

European Patent Office